"we,†or the "Company†) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday. MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit,†...

Key Takeaways SMMT reported a wider Q4 loss of 29 cents per share, with no revenues recorded in 2025.Summit Therapeutics boosted R&D 117% to advance ivonescimab across late-stage NSCLC studies.SMMT's FDA-accepted BLA for ivonescimab in NSCLC faces a decision by Nov. 14, 2026.Summit Therapeutics (SMMT) reported fourth-quarter 2025 loss per share of 29 cents, wider than the Zacks Consensus Estimate of 22 cents. In the year-ago period, the company had incurred a loss of 8 cents per share.The reported loss incl ...

Summit Therapeutics (NasdaqGM:SMMT) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAllen Yang - Chief R&D Strategy OfficerDave Gancarz - Chief Business and Strategy OfficerJosh Schimmer - Senior Managing Director and Leader in Biotechnology Equity ResearchMaky Zanganeh - Co-CEO and PresidentManmeet S. Soni - COO and CFOMark Schwartz - Vice ChairmanRobert Duggan - Co-Chief Executive Officer and Chairman of the BoardConference Call ParticipantsAsthika Goonewardene - Managing Director ...

Summit Therapeutics (NasdaqGM:SMMT) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAllen Yang - Chief R&D Strategy OfficerDave Gancarz - Chief Business and Strategy OfficerJosh Schimmer - Senior Managing Director and Leader in Biotechnology Equity ResearchMaky Zanganeh - Co-CEO and PresidentManmeet S. Soni - COO and CFOMark Schwartz - Vice ChairmanRobert Duggan - Co-Chief Executive Officer and Chairman of the BoardConference Call ParticipantsAsthika Goonewardene - Managing Director ...

Summit Therapeutics (NasdaqGM:SMMT) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Speaker10Good afternoon, welcome to Summit, Summit Therapeutics Q4 and year-end 2025 earnings call. All participants will be in listen-only mode until the question and answer session portion of this call. We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the compan ...

Summit Therapeutics Q4 & FY 2025 Earnings Call February 23, 2026 4:30pm ET Forward Looking Statement Any statements in this presentation about the Company's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc., the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product candidat ...

or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36866 Summit Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 37-1979717 (State or Other Jurisdiction of Incorporation or Organization) _____________________________ FORM 10-K _____________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ...

Core Viewpoint - Summit Therapeutics Inc. will announce its fourth quarter and full year 2025 financial results and provide an operational update on February 23, 2026, after market close [1] Group 1 - The earnings call will be hosted via a live webcast at 4:30 PM ET [1] - The webcast will be accessible through the company's website, www.smmttx.com [1] - An archived edition of the session will be made available following the live event [1]

Group 1 - Summit Therapeutics (NASDAQ:SMMT) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a projected median 1-year price target of $57.98, indicating a strong upside of over 296% [1] - The U.S. FDA has accepted Summit Therapeutics' application for ivonescimab, a lung cancer treatment, with a decision date set for November 14, 2026, based on data from the global phase III HARMONi trial [2][4] - The application targets a market gap for approximately 14,000 eligible U.S. patients annually and is supported by a partnership with Akeso for commercial exposure in China, positioning the company for potential entry into the U.S. oncology market [3] Group 2 - Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing ivonescimab, a bispecific antibody that combines PD-1 blockade and anti-angiogenesis in a single molecule, and is currently conducting Phase III clinical trials for non-small cell lung cancer [4]

Core Viewpoint - Summit Therapeutics Inc. (NASDAQ:SMMT) is identified as an oversold stock with a Buy rating reaffirmed by H.C. Wainwright, highlighting the FDA's acceptance of the Biologics License Application for ivonescimab as a significant positive development [1][3]. Group 1: FDA Approval and Timeline - The FDA accepted the Biologics License Application for ivonescimab, which is intended for use in patients with EGFR-mutated non-small cell lung cancer [3]. - The Prescription Drug User Fee Act goal action date set by the FDA is November 14, 2026, indicating a clear timeline for potential approval [3]. Group 2: Valuation and Price Target - H.C. Wainwright's valuation model estimates an enterprise value of approximately $34 billion, supporting a 12-month price target of $40 per share [2]. - The valuation is based on an 8% discount rate and a 4% terminal growth rate, reflecting confidence in the ivonescimab data and the established nature of PD-1 as a target [2]. Group 3: Company Overview - Summit Therapeutics is a biopharmaceutical company focused on developing innovative treatments for infectious and cancerous diseases [4].